Thromboembolic neurologic events in patients with antiphospholipid-antibody syndrome.
Lenzi
G L
GL
Lenzi
J
J
Mostardini
C
C
D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000276:immunology; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications* / Q000276:immunology; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D020766:Intracranial Embolism / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D020767:Intracranial Thrombosis / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology
D000925:Anticoagulants; D001241:Aspirin